Genetron Holdings Limited (“Genetron Health” or the “Company”,
Nasdaq: GTH), a leading precision oncology platform company in
China that specializes in offering molecular profiling
tests, today announced its participation in the launch of a
major national research project for early screening of lung and
digestive system cancers led by China’s Ministry of Science and
Technology (“MOST”).
Based on the Company’s proprietary technology,
Mutation CapsuleTM, Genetron Health is collaborating with the
National Cancer Center and the Cancer Hospital, Chinese Academy of
Medical Sciences (“CAMS”) for the second time, to provide key
technological contributions for the "Liquid Biopsy-based Malignant
Tumor Early Screening Technology Research and Development Project”.
The launch meeting for the project was held in Beijing on August
29.
At the meeting, representing Genetron Health was
Sizhen Wang, the Company’s co-founder and CEO. Other attendees at
the event included Jie He, Academician of Chinese Academy of
Sciences, Director of National Cancer Center and President of
Cancer Hospital, CAMS; Jie Wang, Director of Department of
Oncology, Cancer Hospital, CAMS; and Qian Liu, professor at the
Cancer Hospital, CAMS.
The project’s goal is to achieve a breakthrough in
the key technologies of liquid biopsy for cancer screening. Under
this premise, the project targets to build a highly sensitive,
highly specific, efficient and affordable liquid biopsy-based early
detection technology platform, and develop proprietary cancer
screening and early detection tests. The project will focus on lung
and digestive system cancers, and is designed to include a
multi-center, prospective cohort study in lung cancer of 120,000
high-risk individuals in 20 provinces, as well as a cohort study in
digestive system cancer of more than 100,000 patients in urban
areas in China. Currently, Genetron Health is the only company in
China participating in national key research and development
projects organized by the Ministry of Science and Technology for
liver, lung and digestive cancer early screening.
“Cancer has become the leading cause of death in
China and is a serious threat to people’s health and lives, yet
most patients who seek treatment are already at a terminal stage,”
said Jie He. “The 2019 government work report expresses the need to
promote early screening, early detection and treatment, and
scientific research on cancers, aiming at solving this critical
problem of people’s livelihood. The launch of this project
indicates that preventative screening and early detection of
cancers has become a major research and development direction for
the Ministry of Science and Technology, and it is also part of the
national strategy. We hope to increase the depth, prevalence and
practicability of cancer early screening, early detection and
treatment research to benefit cancer patients.”
“Early detection and treatment are the most
effective ways to improve clinical outcomes in cancer patients. We
choose to partner with Genetron Health for its leading technology
capabilities and we expect to develop a proprietary malignant tumor
screening and early detection testing kit and implement into
clinical use to significantly improve the cure rates of these types
of cancer for our citizens,” said Jie Wang.
“The importance of early cancer screening cannot be
overemphasized. However, existing examinations lack precise and
high-quality tumor screenings and only use a single biomarker
target. Early cancer diagnosis and screening generally does not
meet the standard of specificity and sensitivity, which will
mislead patients. With this national research project, we hope to
achieve technology breakthroughs and move past the challenges of
current clinical screenings,” said Qian Liu.
Genetron Health, as a leading innovator in the
field of early cancer screening in China, plans to adopt its
self-developed Mutation CapsuleTM technology for this project.
Mutation CapsuleTM requires only a small amount of blood to
simultaneously detect methylation and several types of ctDNA
alternations including SNV, Indel, CNV, etc. This will allow
multiple tests to be performed on one sample without sacrificing
sensitivity. The Mutation Capsule technology has shown high
sensitivity and specificity preliminary data in the early screening
study of liver cancer.
“We are honored to be involved in this major
government-led project based on our Mutation CapsuleTM technology,
which highlights our technological strength in cancer early
screening. In addition, we are delighted that we are able to apply
this technology beyond liver cancer and now into lung and digestive
system cancers,” said Sizhen Wang. “We will continue to expand our
early screening research into more types of cancer and to
accelerate the clinical development and commercialization effort.
Our goal is to develop tests with high performance and affordable
pricing in order to reduce cancer-related healthcare expenses in
our country, and more importantly, to save more lives.”
About Genetron Health Early Screening for Liver
Cancer In March 2019, Genetron Health, in collaboration with the
National Cancer Center and the Cancer Hospital, CAMS, deployed
Mutation CapsuleTM technology to complete a prospective cohort
study in liver cancer early screening (the HCCscreenTM) on
hepatitis B virus carriers using cell free DNA (cfDNA) and protein
markers. Results were published in Proceedings of the National
Academy of Sciences (PNAS), cited in the Guidelines for Diagnosis
and Treatment of Primary Liver Cancer (2019 edition) issued by the
National Health Commission, and Genetron Health was approved to
join a Major National Science and Technology Project by MOST.
Genetron Health has since continued to optimize the
Mutation CapsuleTM platform and liver early screening test in its
ongoing cohort study with 4,500 HBsAg+ individuals. Preliminary
data from 297 patients at one center demonstrated over 92%
sensitivity, 93% specificity and a 35% positive predictive
value.
About Genetron Holdings LimitedGenetron Holdings
Limited (“Genetron Health” or the “Company”) (Nasdaq:GTH)is a
leading precision oncology platform company in China that
specializes in cancer molecular profiling and harnesses advanced
technologies in molecular biology and data science to transform
cancer treatment. The Company has developed a comprehensive
oncology portfolio that covers the entire spectrum of cancer
management, addressing needs and challenges from early screening,
diagnosis and treatment recommendations, as well as continuous
disease monitoring and care. Genetron Health also partners with
global biopharmaceutical companies and offers customized services
and products. For more information, please visit
ir.genetronhealth.com.
Safe Harbor StatementThis press release contains
forward-looking statements within the meaning of federal securities
laws, including statements regarding the potential benefits and
advantages of Genetron Health’s Mutation Capsule™ technology, which
involve risks and uncertainties that could cause the actual results
to differ materially from the anticipated results and expectations
expressed in these forward-looking statements. These statements are
made under the “safe harbor” provisions of the U.S. Private
Securities Litigation Reform Act of 1995. Statements that are not
historical facts, including statements about the Company’s beliefs
and expectations, are forward-looking statements. Forward-looking
statements involve inherent risks and uncertainties, and a number
of factors could cause actual results to differ materially from
those contained in any forward-looking statement. In some cases,
forward-looking statements can be identified by words or phrases
such as “may”, “will,” “expect,” “anticipate,” “target,” “aim,”
“estimate,” “intend,” “plan,” “believe,” “potential,” “continue,”
“is/are likely to” or other similar expressions. Further
information regarding these and other risks, uncertainties or
factors is included in the Company’s filings with the SEC. All
information provided in this press release is as of the date of
this press release, and the Company does not undertake any duty to
update such information, except as required under applicable
law.
Investor Relations Contacts US:
Hoki Luk Head of Investor Relations
Email: hoki.luk@genetronhealth.com Phone: +1 (408)
204-5343
Stephanie Carrington Westwicke, an ICR Company
Email: Stephanie.Carrington@westwicke.com Phone: +1 (646)
277-1282
Asia: Bill Zima ICR, Inc.
Email: bill.zima@icrinc.com GenetronIR@icrinc.com
Media Relations Contact Edmond
Lococo ICR Edmond.Lococo@icrinc.com Mobile: +86
138-1079-1408genetron.pr@icrinc.com
Genetron (NASDAQ:GTH)
Historical Stock Chart
From May 2024 to Jun 2024
Genetron (NASDAQ:GTH)
Historical Stock Chart
From Jun 2023 to Jun 2024